Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

Simplified IVF Brings First Births in Mobile Lab in South Africa

July 11, 2025

In a breakthrough for reproductive health access, the first babies—Milayah and Rossouw—were born following IVF procedures conducted in a mobile laboratory designed to deliver simplified,...

Novel Cancer Enzyme Inhibition Discovered from Sea Cucumber Sugar

July 11, 2025

Researchers identified a unique sugar molecule from the sea cucumber Holothuria floridana that potently inhibits sulfatase-2 (Sulf-2), an enzyme facilitating cancer cell invasion. Structural...

New CRISPR Center to Accelerate Pediatric Gene Editing Therapies

July 11, 2025

The Chan Zuckerberg Initiative and Innovative Genomics Institute launched the Center for Pediatric CRISPR Cures, backed by a $20 million grant. The Center aims to extend personalized CRISPR gene...

Early Clinical Success for Prader-Willi Drug and Rare Obesity Oral Agent

July 11, 2025

Soleno Therapeutics reported preliminary second quarter sales of $31 to $33 million for its Prader-Willi syndrome drug Vykat XR, surpassing analyst expectations despite a high annual price point....

Merck Expands Respiratory Portfolio With $10B Verona Acquisition

July 11, 2025

Merck & Co. has agreed to acquire Verona Pharma for approximately $10 billion, adding the inhaled dual inhibitor Ohtuvayre to its respiratory pipeline. Ohtuvayre, approved by the FDA in 2024 for...

AbbVie Invests $700M in Trispecific Antibody for Multiple Myeloma

July 11, 2025

AbbVie has agreed to pay $700 million upfront to IGI Therapeutics for licensing rights to ISB-2001, a trispecific antibody candidate targeting multiple myeloma. The antibody engages three...

FDA Implements Partial Transparency With Release of Drug Rejection Letters

July 11, 2025

The U.S. Food and Drug Administration published an initial batch of over 200 complete response letters (CRLs) detailing application deficiencies from drug approval processes between 2020 and 2024....

AI and Protein Design Propel New Advances Against Resistant Bacteria and Drug Discovery

July 11, 2025

Australian researchers used artificial intelligence to design de novo proteins that inhibit the growth of antibiotic-resistant bacteria such as Escherichia coli by blocking hemoglobin transporters...

Soleno Therapeutics Surpasses Expectations in Prader-Willi Syndrome Drug Launch

July 11, 2025

Soleno Therapeutics reported preliminary net sales of its Prader-Willi syndrome drug, Vykat XR, between $31 million and $33 million for Q2 2025, exceeding Wall Street forecasts. Since U.S....

Center for Pediatric CRISPR Therapies Founded to Expand Genome Editing Cures

July 11, 2025

The Chan Zuckerberg Initiative and the Innovative Genomics Institute have launched the Center for Pediatric CRISPR Cures, a $20 million project dedicated to developing personalized CRISPR-based...

Nuclidium and Actithera Secure Major Funding for Radiopharmaceutical Development

July 11, 2025

European radiopharmaceutical startups Nuclidium and Actithera have completed significant financing rounds to advance their platforms. Nuclidium raised approximately $99 million in Series B funding...

Advances in Diagnostics and Liquid Biopsy Expand Cancer and Disease Monitoring

July 11, 2025

University of Chicago researchers developed a liquid biopsy method utilizing microbiome-derived cell-free RNA methylation patterns to predict colorectal cancer more accurately than current...

Biopharma IPO, Layoffs, and Investment Landscape Reflect Market Caution

July 11, 2025

Biopharma financing in Q2 2025 grew modestly to $16 billion, up from Q1 but below historical highs. Despite available capital exceeding $55 billion across numerous venture funds, investment focus...

Merck’s $10 Billion Bet on COPD Drug Verona Pharma

July 11, 2025

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, a significant move to bolster its respiratory portfolio as it prepares for the patent expiry of its cancer blockbuster Keytruda....

AbbVie Secures $700M Trispecific Antibody for Multiple Myeloma

July 11, 2025

AbbVie recently inked a licensing agreement with IGI Therapeutics and its subsidiary Ichnos Glenmark Innovation for a trispecific antibody, ISB-2001, targeting multiple myeloma and potentially...

FDA Publishes Complete Response Letters in Transparency Shift

July 11, 2025

The U.S. Food and Drug Administration (FDA) has for the first time publicly released over 200 complete response letters (CRLs) issued between 2020 and 2024 as part of a transparency initiative....

AI-Designed Protein Targets Antibiotic-Resistant Bacteria

July 11, 2025

Australian researchers from Monash University and collaborators employed artificial intelligence (AI) to design a novel protein that inhibits heme piracy by pathogenic Escherichia coli, a...

Radiopharmaceuticals Gain Momentum with Major Fundraises

July 11, 2025

Radiopharmaceutical companies Nuclidium and Actithera have raised significant funds to advance their drug pipelines. Nuclidium completed a $99 million Series B round to support clinical...

Soleno Therapeutics’ Prader-Willi Drug Surpasses Sales Expectations

July 11, 2025

Soleno Therapeutics reported that its Prader-Willi syndrome drug, Vykat XR, generated estimated net revenues between $31 million and $33 million in Q2 2025, exceeding Wall Street projections....

Chan Zuckerberg Initiative and IGI Fund Pediatric CRISPR Center

July 11, 2025

The Chan Zuckerberg Initiative (CZI) and the Innovative Genomics Institute (IGI) have jointly funded the Center for Pediatric CRISPR Therapies with a $20 million grant. The Center aims to develop...